Protective Effects of Garlic-Derived S-Allylmercaptocysteine on IL-1 β-Stimulated Chondrocytes by Regulation of MMPs/TIMP-1 Ratio and Type II Collagen Expression via Suppression of NF- κ B Pathway

Biomed Res Int. 2017:2017:8686207. doi: 10.1155/2017/8686207. Epub 2017 Dec 3.

Abstract

Background: Garlic-derived S-allylmercaptocysteine (SAMC) has widely been used in many disease therapies. However, the potential effects and mechanism of SAMC on IL-1β-stimulated chondrocytes are unclear.

Methods: Chondrocytes were isolated, and 5 ng/mL of IL-1β was added to mimic the in vitro osteoarthritis (OA) model. SAMC (20 and 60 μM) was used for the treatment in OA model. Cell viability was assessed by MTT method. Western blotting, Quantitative RT-PCR, and ELISA were performed to evaluate the mechanisms in SAMC treated OA model.

Results: Following 48 h of IL-1β exposure, SAMC exhibited protection effect on IL-1β-injured chondrocyte viability. Type II collagen was elevated with reduced degradation products, as a consequence of altered MMPs/TIMP-1 ratio after SAMC treatment in IL-1β-treated chondrocytes. The protein and mRNA level of TNF-α in cellular supernatant and cells were downregulated in a dose-dependent manner. Besides, IκBα in cytoplasmic fraction was increased, while p65 level in nuclear fraction was decreased after SAMC treatment in OA.

Conclusions: This study showed that SAMC may play a protective role in IL-1β induced osteoarthritis (OA) model. This effect may be through inhibiting the NF-κB signaling pathway, therefore altering the MMPs/TIMP-1 ratio change which induced type II collagen destruction and decreasing inflammatory cytokine secretion such as TNF-α.

MeSH terms

  • Chondrocytes / drug effects*
  • Chondrocytes / pathology
  • Collagen Type II / genetics
  • Cysteine / administration & dosage
  • Cysteine / analogs & derivatives*
  • Cysteine / chemistry
  • Garlic / chemistry*
  • Gene Expression / drug effects
  • Humans
  • Interleukin-1beta / administration & dosage
  • Matrix Metalloproteinases / genetics
  • NF-kappa B / genetics
  • Osteoarthritis / drug therapy*
  • Osteoarthritis / genetics
  • Osteoarthritis / pathology
  • Signal Transduction / drug effects
  • Tissue Inhibitor of Metalloproteinase-1 / genetics
  • Transcription Factor RelA / genetics
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • Collagen Type II
  • Interleukin-1beta
  • NF-kappa B
  • RELA protein, human
  • S-allylmercaptocysteine
  • TIMP1 protein, human
  • Tissue Inhibitor of Metalloproteinase-1
  • Transcription Factor RelA
  • Tumor Necrosis Factor-alpha
  • Matrix Metalloproteinases
  • Cysteine